Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
32
Recruiting, any sponsor type, condition "allergic rhinitis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed739
32 trials
Showing 1 to 25, recently updated first.
- Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-069.Pivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT07904195 · 250 participants (planned) · Start Apr 15, 2026 · Primary completion Jul 2029
Drug: EP-088_MM09; Placebo · For: Allergic Rhinitis; Allergic Rhinoconjunctivitis; Allergic Asthma
Sites: Covilha, Portugal; Portimão, Portugal; Ponta Delgada, Portugal · 16 sites in all
- Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.Pivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT07904052 · 250 participants (planned) · Start Feb 24, 2026 · Primary completion Jul 2029
Drug: EP-088_MM09; Placebo · For: Allergic Rhinitis; Allergic Rhinoconjunctivitis; Allergic Asthma
Sites: Coimbra, Portugal; Lisbon, Portugal; Porto, Portugal · 16 sites in all
Dr. Anne EllisAcademic, hospital or other
NCT07801625 · 12 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 31, 2027
Drug: Standardized Allergen Extract, Timothy Grass (Phleum pratense); Standardized Allergen Extract, Timothy Grass (Phleum pratense) · For: Allergic Rhinoconjunctivitis
Sites: Kingston, Canada
Immunomic Therapeutics, Inc.Industry
NCT07726147 · 45 participants (planned) · Start Jun 20, 2026 · Primary completion Feb 2028
Drug: ITI-9001 · For: Allergen Immunotherapy
Sites: Tokyo, Japan
Hull University Teaching Hospitals NHS TrustGovernment (non-federal)
NCT06876506 · 80 participants (planned) · Start Jan 21, 2026 · Primary completion May 31, 2027
Drug: Allergen Specific Immunotherapy; Allergen Specific Immunotherapy · For: Pollen Allergy; Venom Allergy
Sites: Hull, United Kingdom
- Rupatifen Fumarate Capsules in Patients With Seasonal Allergic RhinitisPivotal-lookingRecruiting
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Industry
NCT07711262 · 550 participants (planned) · Start Aug 18, 2026 · Primary completion Oct 2027
Drug: Rupatifen Fumarate Capsules; Rupatadine Fumarate Tablets and 2 more · For: Seasonal Allergic Rhinitis
Sites: Baoding, China; Cangzhou, China; Shijiazhuang, China · 18 sites in all
- Study on the Treatment of Adolescent Patients With Seasonal Allergic RhinitisPivotal-lookingRecruiting
Chengdu Kangnuoxing Biopharma,Inc.Industry
NCT07678931 · 136 participants (planned) · Start Aug 13, 2026 · Primary completion Dec 2026
Drug: Stapokibart; Placebo · For: Seasonal Allergic Rhinitis (SAR)
Sites: Beijing, China; Langfang, China; Baoding, China · 27 sites in all
- Study of Yupingfeng Powder Treating Allergic Rhinitis (AR)Pivotal-lookingRecruiting
Chinese University of Hong KongAcademic, hospital or other
NCT06608017 · 140 participants (planned) · Start Mar 27, 2025 · Primary completion Dec 31, 2026
Drug: Chinese Herbal Medicine granules · For: Allergic Rhinitis
Sites: Shatin, Hong Kong
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT06436534 · 50 participants (planned) · Start May 24, 2024 · Primary completion Oct 2026
Drug: Ganciclovir Oral Capsule; Ganciclovir Simulant Oral Capsule and 1 more · For: Rhinitis, Allergic
Sites: Wuhan, China
Karolinska InstitutetAcademic, hospital or other
NCT07651891 · 40 participants (planned) · Start Aug 1, 2026 · Primary completion Oct 1, 2027
Drug: ALK Alutard SQ Dog · For: Allergic Rhinitis; Asthma (Diagnosis)
Sites: Lund, Sweden; Trelleborg, Sweden
- PollenVax Subcutaneous Immunotherapy for Mugwort Pollen-Induced Allergic RhinitisPivotal-lookingRecruiting
Kazakh National Agrarian UniversityAcademic, hospital or other
NCT07563439 · 138 participants (planned) · Start May 1, 2026 · Primary completion Sep 2026
Drug: Recombinant Artemisia vulgaris allergen Art v 1 with Montanide ISA-51 adjuvant; Montanide ISA-51 placebo emulsion · For: Rhinitis Allergic
Sites: Almaty, Kazakhstan
- The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen ImmunotherapyRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT04544774 · 200 participants (planned) · Start Jul 16, 2020 · Primary completion Dec 2026
Drug: AIT · For: Perennial Allergic Rhinitis; Seasonal Allergic Rhinitis; Local Allergic Rhinitis
Sites: Leuven, Belgium; Bruges, Belgium
- Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic RhinitisRecruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07398859 · 300 participants (planned) · Start Mar 19, 2026 · Primary completion Nov 2026
Drug: TQH2722 injection · For: Seasonal Allergic Rhinitis
Sites: Beijing, China; Chongqing, China; Baoding, China · 30 sites in all
University of ZurichAcademic, hospital or other
NCT06960382 · 36 participants (planned) · Start Aug 20, 2025 · Primary completion May 31, 2027
Drug: ALUTARD SQ® Felis domesticus · For: Allergic Rhinitis; Allergic Asthma
Sites: Zurich, Switzerland
- Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or DfPivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT07348302 · 736 participants (planned) · Start Apr 2, 2025 · Primary completion Apr 27, 2029
Drug: Allergen Immunotherapy Extract · For: Rhinitis; Rhinoconjunctivitis
Sites: Nueve de Julio, Argentina; Rosario, Argentina; Buenos Aires, Argentina · 19 sites in all
- A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen ExposurePivotal-lookingRecruiting
Alixer Nexgen Therapeutics LimitedIndustry
NCT07219849 · 164 participants (planned) · Start Oct 17, 2025 · Primary completion Apr 2026
Drug: ALDP001 Nasal Spray; Placebo Nasal spray · For: Seasonal Allergic Rhinitis (SAR)
Sites: Mississauga, Canada
- Study of CM310 in Patients With Uncontrolled Seasonal Allergic RhinitisPivotal-lookingRecruiting
Beijing Tongren HospitalAcademic, hospital or other
NCT06300203 · 120 participants (planned) · Start Mar 18, 2024 · Primary completion Jun 30, 2026
Drug: Interleukin-4 receptor responders · For: Seasonal Allergic Rhinitis
Sites: Beijing, China
- Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With AsthmaPivotal-lookingRecruiting
Daewon Pharmaceutical Co., Ltd.Industry
NCT07168473 · 274 participants (planned) · Start Sep 9, 2024 · Primary completion Aug 31, 2026
Drug: Experimental; Comparator · For: Perennial Allergic Rhinitis Accompanied by Asthma
Sites: Seoul, South Korea
- A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic RhinitisPivotal-lookingRecruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07154342 · 150 participants (planned) · Start Aug 15, 2025 · Primary completion Apr 30, 2026
Drug: GR1802 injection; Placebo · For: Allergic Rhinitis, Seasonal
Sites: Wuhan, China
- Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic RhinitisPivotal-lookingRecruiting
Tanta UniversityAcademic, hospital or other
NCT07115342 · 120 participants (planned) · Start Aug 1, 2025 · Primary completion Oct 30, 2025
Drug: Standard Allergic Rhinitis Treatment · For: Allergic Rhinitis; Allergic Rhinitis (AR)
Sites: Tanta, Egypt
- Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.Pivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT04898283 · 180 participants (planned) · Start May 31, 2021 · Primary completion Oct 2026
Drug: 10,000 MG01 +10,000 T521; 30,000 MG01 +10,000 T521 · For: Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergic
Sites: Valladolid, Spain; Tarancón, Spain; Alcalá de Henares, Spain · 27 sites in all
- Efficacy and Safety Evaluation for the Treatment of Allergy Against MitesPivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT04435990 · 150 participants (planned) · Start Oct 6, 2020 · Primary completion Dec 2026
Drug: 10,000 MM09; 30,000 MM09 and 1 more · For: Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergic
Sites: Santiago de Compostela, Spain; Elche, Spain; Torrevieja, Spain · 32 sites in all
- Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive PollenPivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT04891237 · 180 participants (planned) · Start Jun 14, 2021 · Primary completion Jan 2026
Drug: 10,000 MG01 + 10,000 T517; 30,000 MG01 + 10,000 T517 · For: Rhinitis, Allergic; Rhinoconjunctivitis; Asthma, Allergic
Sites: Tarancón, Spain; Alcalá de Henares, Spain; Tres Cantos, Spain · 32 sites in all
Zheng LiuAcademic, hospital or other
NCT06462417 · 15 participants (planned) · Start Jul 11, 2024 · Primary completion Jun 30, 2025
Drug: Arbidol · For: Allergic Rhinitis
Sites: Wuhan, China · 2 sites in all
- Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic RhinitisPivotal-lookingRecruiting
Shanghai Mabgeek Biotech.Co.LtdIndustry
NCT06846385 · 160 participants (planned) · Start Mar 20, 2025 · Primary completion May 31, 2025
Drug: Placebo; MG-K10 Humanized Monoclonal Antibody Injection · For: Seasonal Allergic Rhinitis
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.